Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism

Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement

(2014) Jacqueline Jonklaas et al.   THYROID

Management of adrenal cancer: a 2013 update

(2014) M. Terzolo et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993

(2013) Thomas M.A. Kerkhofs et al.   EUROPEAN JOURNAL OF CANCER

Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center

(2013) Montserrat Ayala-Ramirez et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Update in Adrenocortical Carcinoma

(2013) Martin Fassnacht et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of mitotane treatment on human steroid metabolism: implications for patient management

(2012) L Ghataore et al.   Endocrine Connections

Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients

(2011) Damiano Gullo et al.   PLoS One

Therapeutic Concentrations of Mitotane (o,p′-DDD) Inhibit Thyrotroph Cell Viability and TSH Expression and Secretion in a Mouse Cell Line Model

(2010) Maria Chiara Zatelli et al.   ENDOCRINOLOGY

Drugs that suppress TSH or cause central hypothyroidism

(2009) Bryan R. Haugen   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly

(2008) F. Daffara et al.   ENDOCRINE-RELATED CANCER